Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine

27 Apr, 2020
Company Signs Agreement with Emergent BioSolutions in the U.S. As Part of its Investment
First in Series of Anticipated Strategic Collaborations Designed to Further the Company’s Goal of Ensuring Global Supply of a Safe and Effective Vaccine for COVID-19

Johnson & Johnson (the Company) (NYSE: JNJ) on 23rd April 2020 announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to support the manufacturing of its lead investigational COVID-19 vaccine candidate. This is the first in a series of prospective global collaboration agreements designed to accelerate manufacturing of Johnson & Johnson’s COVID-19 vaccine candidate, and further the Company’s goal to supply more than one billion doses of the vaccine globally.

Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, said, “We have set a high bar. Johnson & Johnson has committed to rapidly produce and supply more than one billion doses of a safe and effective vaccine globally. Our collaboration with Emergent is proof that we are moving quickly to deliver on that promise.”

Under the terms of this manufacturing agreement, Johnson & Johnson is investing to expand drug substance capacity related to the vaccine candidate. Emergent will provide drug substance manufacturing services with its molecule-to-market CDMO offering, beginning in 2020, and will also reserve operations capacity to potentially support commercial manufacturing of Johnson & Johnson’s COVID-19 vaccine candidate leveraging Janssen’s proven AdVac® and PER.C6® technologies beginning in 2021.

Click here for reference